New heparin dosing for obese heart surgery patients may cut bleeding risk
NCT ID NCT02675647
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study tested whether using ideal body weight (instead of total body weight) to calculate heparin doses during heart-lung bypass reduces excessive bleeding in obese patients. Sixty obese adults scheduled for heart surgery were randomly assigned to receive heparin based on either ideal or total body weight. Researchers measured heparin levels, clotting time, bleeding, and transfusion needs to see if the new dosing is safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SURGERY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Heparin
What this could lead to
If successful, this could lead to safer heparin dosing guidelines for obese patients undergoing heart surgery, reducing bleeding risks.
What could go wrong
This is a small, single-center Phase 4 study with only 60 participants, so results may not apply broadly. The approach may not significantly reduce bleeding or complications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.